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Background
Human immunodeficiency virus (HIV) protease inhibitors show activity against 
Plasmodium falciparum in vitro. We hypothesized that the incidence of malaria in HIV-
infected children would be lower among children receiving lopinavir–ritonavir–
based antiretroviral therapy (ART) than among those receiving nonnucleoside 
reverse-transcriptase inhibitor (NNRTI)–based ART.
Methods
We conducted an open-label trial in which HIV-infected children 2 months to 5 years 
of age who were eligible for ART or were currently receiving NNRTI-based ART 
were randomly assigned to either lopinavir–ritonavir–based ART or NNRTI-based 
ART and were followed for 6 months to 2 years. Cases of uncomplicated malaria 
were treated with artemether–lumefantrine. The primary end point was the incidence 
of malaria.
Results
We enrolled 176 children, of whom 170 received the study regimen: 86 received 
NNRTI-based  ART, and 84 lopinavir–ritonavir–based ART. The incidence of ma-
laria was lower among children receiving the lopinavir–ritonavir–based regimen 
than among those receiving the NNRTI-based regimen (1.32 vs. 2.25 episodes per 
person-year; incidence-rate ratio, 0.59; 95% confidence interval [CI], 0.36 to 0.97; 
P = 0.04), as was the risk of a recurrence of malaria after treatment with arte-
mether–lumefantrine (28.1% vs. 54.2%; hazard ratio, 0.41; 95% CI, 0.22 to 0.76; 
P = 0.004). The median lumefantrine level on day 7 after treatment for malaria was 
significantly higher in the lopinavir–ritonavir group than in the NNRTI group. In 
the lopinavir–ritonavir group, lumefantrine levels exceeding 300 ng per milliliter on 
day 7 were associated with a reduction of more than 85% in the 63-day risk of recur-
rent malaria. A greater number of serious adverse events occurred in the lopinavir–
ritonavir group than in the NNRTI group (5.6% vs. 2.3%, P = 0.16). Pruritus occurred 
significantly more frequently in the lopinavir–ritonavir group, and elevated alanine 
aminotransferase levels significantly more frequently in the NNRTI group.
Conclusions
Lopinavir–ritonavir–based ART as compared with NNRTI-based ART reduced the 
incidence of malaria by 41%, with the lower incidence attributable largely to a sig-
nificant reduction in the recurrence of malaria after treatment with artemether–
lumefantrine. Lopinavir–ritonavir–based ART was accompanied by an increase in 
serious adverse events. (Funded by the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development; ClinicalTrials.gov number, NCT00978068.)
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Malaria and human immunodefi-ciency virus (HIV) infection impose immense and overlapping burdens in 
sub-Saharan Africa. Prophylaxis with trimetho-
prim–sulfamethoxazole and insecticide-treated 
bed nets reduce the incidence of malaria among 
HIV-infected children, but protection is incom-
plete, and even with the use of these protective 
strategies, the burden of malaria remains great 
in areas of high-intensity transmission.1 Thus, 
new approaches to the prevention of malaria are 
an important public health priority.
Antiretroviral protease inhibitors show in vitro 
activity against Plasmodium falciparum2-4 (the cause 
of most malaria cases in Africa), probably owing 
to inhibition of plasmodial aspartic proteases 
that are biochemically similar to the HIV-1 pro-
tease.3,5 Lopinavir is the most potent of these 
inhibitors and is active at levels well below those 
achieved with standard doses of coformulated 
lopinavir–ritonavir.2,3 Since lopinavir–ritonavir 
is increasingly available for the treatment of HIV 
infections in Africa, it may represent a valuable 
tool for the prevention of malaria. However, 
because ritonavir inhibits the metabolism of 
many drugs, it has the potential for interactions 
with antimalarial agents, including widely used 
artemisinin-based combination therapies, poten-
tially affecting the efficacy and safety of the 
drugs.6 We assessed the incidence of malaria in 
HIV-infected Ugandan children who were ran-
domly assigned to receive a lopinavir–ritonavir–
based antiretroviral regimen or a nonnucleoside 
reverse-transcriptase inhibitor (NNRTI)–based 
antiretroviral regimen.
Me thods
Study Participants
We conducted the study in Tororo, Uganda, an 
area of high-intensity malaria transmission.7 Eli-
gible children were 2 months to 5 years of age, 
with confirmed HIV infection. Participants had 
either never received antiretroviral therapy (ART) 
and were eligible for initiation of ART according 
to national guidelines or were currently receiving 
standard first-line ART, comprising one NNRTI 
plus two nucleoside reverse-transcriptase inhibi-
tors (NRTIs), and had an HIV RNA level of less 
than 400 copies per milliliter, as assessed in the 
most recent measurement during the preceding 
6 months. A complete description of the entry 
criteria is provided in the Supplementary Appen-
dix and in the protocol, both of which are avail-
able with the full text of this article at NEJM.org. 
The parents or guardians provided written in-
formed consent for the participation of their 
children in the trial.
Study Design
This was an open-label trial with randomization 
stratified at the time of enrollment according to 
prior or no prior receipt of ART. Randomization 
was performed in permuted blocks of 2 or 4. 
Participants received either lopinavir–ritonavir 
(Abbott Laboratories) plus two NRTIs or an 
NNRTI — nevirapine (for children <3 years of 
age) or efavirenz (for children ≥3 years of age) 
— plus two NRTIs. The NRTIs that were used in 
the regimens were lamivudine and zidovudine, 
with stavudine or abacavir replacing zidovudine 
in children who had anemia. Children who were 
already receiving ART were randomly assigned to 
continue their current regimen or to switch to 
lopinavir–ritonavir while continuing the same 
NRTIs. Parents and guardians received counsel-
ing on adherence before the children underwent 
randomization and were given a 4-week supply of 
ART at each monthly visit. Insulated coolers were 
provided when liquid lopinavir–ritonavir was dis-
pensed for young children. Adherence to ART 
was assessed monthly on the basis of caregiver 
reports and pill counts.
Study Procedures
At the time of enrollment, children received a 
long-lasting insecticide-treated bed net, a hygienic 
water-storage container, multivitamins, and tri-
methoprim–sulfamethoxazole to be taken daily. 
Participants received all their medical care at a 
study clinic that was open every day. Routine vis-
its were scheduled every 4 weeks, and routine 
laboratory tests were performed every 12 weeks. 
Parents or guardians were encouraged to bring a 
child to the clinic any time the child was ill. In 
the case of children who presented with a docu-
mented fever (a tympanic temperature ≥38.0°C) 
or a history of fever in the previous 24 hours, 
blood was obtained by finger prick for examina-
tion of a thick blood smear. The diagnosis of 
malaria was made if the smear was positive for 
malaria parasites. Children with uncomplicated 
malaria were treated with artemether–lumefan-
trine, which is the recommended first-line treat-
ment in Uganda, and the parents or guardians 
were instructed to bring the children back for 
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follow-up evaluation on days 1, 2, 3, 7, 14, 21, 
and 28. The administration of each first daily 
dose of artemether–lumefantrine was directly 
observed in the study clinic, and each second 
daily dose was administered at home. A complete 
blood count and measurement of the alanine 
aminotransferase level were performed on days 0 
and 28. From July 13, 2010, through June 8, 2011, 
blood samples were obtained by means of finger 
prick 7 days after initiation of artemether–lume-
fantrine therapy, for measurement of lumefan-
trine levels. After November 15, 2010, electrocar-
diograms were obtained and were read by trained 
study physicians on days 0 and 3 to assess cor-
rected QT (QTc) intervals. Outcomes of malaria 
treatment were classified according to World 
Health Organization (WHO) guidelines.8 Adverse 
events were assessed at every visit and were grad-
ed according to standardized criteria.9
Study Oversight
The study was approved by the Makerere Univer-
sity School of Medicine Research and Ethics 
Committee, the Uganda National Council for Sci-
ence and Technology, and the University of Cali-
fornia, San Francisco, Committee for Human 
Research. Lopinavir–ritonavir was donated by 
Abbott Laboratories, which played no role in the 
design of the study, the accrual or analysis of the 
data, or the preparation of the manuscript. All 
other antiretroviral drugs were available through 
existing distribution systems of the Uganda Min-
istry of Health, through Tororo District Hospital; 
in the event that any of these drugs were not 
available through this process, the drugs were 
purchased by the study team from a reputable 
pharmacy. The antimalarial drugs were pur-
chased by the study team. All the authors vouch 
for the completeness and accuracy of the data 
and analyses and for the fidelity of the study to 
the protocol.
Laboratory Procedures
Parasite density was assessed from blood smears 
as described previously.10 If a participant had a 
recurrence of malaria 4 to 63 days after the ini-
tiation of malaria therapy, genotyping was per-
formed, as described previously, to distinguish 
recrudescence from new infection.10 Lumefan-
trine levels were measured in 25-μl samples as 
described previously.11 The interassay and intra-
assay precision (percentage coefficient of varia-
tion) was 5.3 to 6.1% and 2.2 to 10%, respec-
tively. The interassay and intra-assay accuracy 
was 103.5 to 107.1% and 99.5 to 109.7%, respec-
tively. The lower limit of quantification was 50 ng 
per milliliter. At the time of the diagnosis of ma-
laria, in vitro culturing of selected P. falciparum 
isolates was performed as described previously.12 
After 2 to 4 weeks, aliquots were frozen in glyc-
erol and stored in liquid nitrogen; they were sub-
sequently thawed and cloned by means of a limit-
ing-dilution technique.13 Drug-interaction studies 
were performed on clones from two different pa-
tients with the use of the checkerboard tech-
nique, as described previously.2
Study End Points
The primary end point was the incidence of ma-
laria, which was defined as the number of inci-
dent episodes of malaria per time at risk. Malaria 
that was diagnosed within 14 days after a prior 
episode was not considered to be an incident 
event. The time at risk was calculated as the time 
from the day after initiation of study treatment to 
the last day of observation, minus 14 days after 
each incident episode of malaria. In the calcula-
tion of the time at risk, discounting the 14 days 
after each incident episode of malaria is a stan-
dard approach. Secondary outcomes included the 
incidence of complicated malaria, the efficacy 
and safety of antimalarial therapy, and pharma-
cokinetic characteristics of lumefantrine.
Statistical Analysis
To test the hypothesis that lopinavir–ritonavir–
based ART would reduce the incidence of malar-
ia, we assumed that the incidence of malaria in 
the NNRTI group would be 0.70 episodes per 
person-year and estimated that we would need a 
sample of 300 participants for the study to have 
80% power to show a 35% reduction in the inci-
dence of malaria in the lopinavir–ritonavir group, 
at a two-sided significance level of 0.05. We sub-
sequently observed an incidence of malaria in the 
NNRTI group that was higher than anticipated 
(2.19 episodes per person-year) and revised the 
sample size to 150 participants, who would be 
followed for at least 6 months.
The statistical analysis was performed accord-
ing to the intention-to-treat principle, with the use 
of Stata software, version 11. For the between-
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group comparisons of the incidence of malaria, 
we used a negative binomial regression model. 
Time to events was estimated with the use of the 
Kaplan–Meier product-limit formula, and compari-
sons were made with the use of a Cox propor-
tional-hazards model with adjustment for repeated 
measures in the same patient. Pairwise compari-
sons of categorical and continuous variables at the 
level of each episode of malaria were made with 
the use of generalized estimating equations with 
adjustment for repeated measures in the same pa-
tient and with exchangeable correlation and robust 
176 Were enrolled and underwent
randomization
404 Children were screened
228 Were excluded
136 Were not eligible for ART
34 Were on ART with detectable viral load
32 Were HIV-negative
8 Had not received ART but had prior exposure
to nevirapine
3 Were on ART for <12 mo
3 Were >5 yr of age
3 Had active severe medical condition
3 Failed to return for laboratory results
2 Had abnormal screening laboratory results
1 Lived >30 km from study clinic
1 Was on second-line ART
1 Intended to move from study area
1 Refused informed consent
89 Were assigned to receive
NNRTI-based ART
87 Were assigned to receive
lopinavir–ritonavir–based ART
3 Did not initiate study drug
2 Were awaiting initiation
of ART
1 Died
3 Did not initiate study drug
2 Were awaiting initiation
of ART
1 Was unable to be located
for >60 days
86 Initiated study drugs 84 Initiated study drugs
6 Were withdrawn from study
2 Died
2 Were unable to comply
with study
1 Was withdrawn by investi-
gators
1 Moved from study area
1 Was withdrawn from study
owing to relocation from
study area
80 Were included in the follow-up
through end of observation period
83 Were included in the follow-up
through end of observation period
Figure 1. Screening, Enrollment, Randomization, and Follow-up.
ART denotes antiretroviral therapy, HIV human immunodeficiency virus, and NNRTI nonnucleoside reverse-transcriptase 
inhibitor.
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standard errors. P values of less than 0.05 were 
considered to indicate statistical significance.
R esult s
Study Participants and Follow-up
From September 2009 through July 2011, a total 
of 404 children were screened for eligibility; 228 
were found not to be eligible, including 136 who 
did not meet the criteria for initiation of ART 
(Fig. 1). A total of 176 children underwent ran-
domization: 89 were assigned to NNRTI-based 
ART and 87 to lopinavir–ritonavir–based ART. 
Study drugs were initiated in 86 children in the 
NNRTI group and 84 in the lopinavir–ritonavir 
group, and these children were followed for a 
median of 366 days. The baseline characteristics 
were similar between the two groups (Table 1). 
During monthly routine assessments, 97% of 
caregivers reported 100% adherence to ART.
Incidence of Malaria
Among the study participants, there were 285 
new episodes of malaria during 162 person-years 
of follow-up; all the episodes of malaria were due 
to P. falciparum infection. The incidence of ma-
laria was significantly lower in the lopinavir–
ritonavir group than in the NNRTI group (1.32 vs. 
2.25 episodes per person-year), resulting in pro-
tective efficacy of 41% with lopinavir–ritonavir 
(incidence rate ratio, 0.59; 95% confidence inter-
val [CI], 0.36 to 0.97; P = 0.04) (Table 2). Compli-
cated malaria occurred infrequently, with a simi-
lar incidence in the two groups. To assess the 
effect of ART independently of potential interac-
tions with antimalarial therapy after treatment 
for malaria, we compared the two groups with 
respect to the time to the first episode of malaria 
(Fig. 2A). The 6-month risk of a first episode of 
malaria was 40.7% in the lopinavir–ritonavir 
group, as compared with 52.5% in the NNRTI 
group (hazard ratio with lopinavir–ritonavir, 
0.71; 95% CI, 0.45 to 1.12; P = 0.14) (Table 2).
Efficacy and Safety Outcomes after 
Antimalarial Therapy
Of the 285 new episodes of malaria, 281 (98.6%) 
were uncomplicated and were treated with arte-
mether–lumefantrine. To assess the effect of 
potential interactions between ART and arte-
mether–lumefantrine, the risks of recurrent para-
sitemia and recurrent malaria were compared 
between the two groups. The 28-day risk of re-
current parasitemia was significantly lower in 
the lopinavir–ritonavir group than in the NNRTI 
group (14.0% vs. 40.8%, P = 0.004), as was the 
63-day risk of recurrent malaria (28.1% vs. 54.2%, 
P = 0.004) (Table 2 and Fig. 2B). Among patients 
in whom parasites were cleared by 7 days, there 
were 111 episodes of recurrent malaria within 63 
days; 107 cases were successfully genotyped, and 
all were classified as new infections. Resolution 
of fever, parasite clearance, and recovery of mean 
Table 1. Baseline Characteristics of Participants Who Received Study Drugs.*
Characteristic
NNRTI-Based 
ART (N = 86)
Lopinavir–Ritonavir– 
Based ART (N = 84)
Age — yr
Median 3.1 2.9
Range 0.5–5.9 0.7–6.0
Female sex — no. (%) 41 (48) 41 (49)
No previous ART — no. (%) 58 (67) 57 (68)
WHO clinical HIV stage — no. (%)
I 66 (77) 60 (71)
II 15 (17) 16 (19)
III 1 (1) 2 (2)
IV 4 (5) 6 (7)
CD4 percentage†
No previous ART
Median 16 14
Range 2–43 2–44
Previous ART
Median 30 31
Range 10–45 8–51
Viral load — log10 copies/ml
No previous ART
Median 5.5 5.4
Range BLD–6.4 BLD–6.4
Previous ART
Median BLD BLD
Range BLD BLD
Hemoglobin — g/dl 10.6±1.5 10.4±1.3
Positive blood smear for asexual 
parasites — no. (%)
11 (13) 10 (12)
* Plus–minus values are means ±SD. There were no significant differences be-
tween the groups in baseline characteristics. BLD denotes below the level of 
detection (<400 copies per microliter), and WHO World Health Organization.
† CD4 percentage is the preferred measurement for children younger than 5 years 
of age, as recommended by the WHO. The percentage represents the percent-
age of white cells that are CD4 cells.
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hemoglobin levels after antimalarial treatment 
were similar in the two groups (Table S1 in the 
Supplementary Appendix). There were no signifi-
cant differences in the rates of adverse events 
over the course of the 28-day period after anti-
malarial therapy, except that pruritus was more 
common in the lopinavir–ritonavir group (5.6% 
vs. 1.2%, P = 0.04), and elevation of alanine ami-
notransferase levels occurred more frequently in 
the NNRTI group (13.5% vs. 3.3%, P = 0.003) (Ta-
ble S2 in the Supplementary Appendix). A total of 
10 serious adverse events occurred during the 
standard WHO 28-day period for malaria follow-
up, with a trend toward a higher frequency in the 
lopinavir–ritonavir group (5.6% vs. 2.3%, P = 0.16). 
All the serious adverse events were considered to 
be unrelated to the study drugs, with the excep-
tion of one episode of the Stevens–Johnson syn-
drome in the NNRTI group, which led to discon-
tinuation of the study drug, and two episodes of 
neutropenia in the lopinavir–ritonavir group, 
which resolved without discontinuation of thera-
py. Electrocardiograms obtained on day 3 after 
initiation of treatment for malaria in a subgroup 
of 120 patients showed no episodes of prolonga-
tion of the QTc interval (Table S2 in the Supple-
mentary Appendix).
Pharmacokinetic Characteristics of Malaria 
Therapy and Drug Interactions
During the period in which blood samples were 
obtained to assess drug levels, there were 103 epi-
sodes of malaria in the NNRTI group and 73 in 
the lopinavir–ritonavir group; lumefantrine levels 
were successfully measured on day 7 after initia-
tion of malaria treatment in the case of 92 epi-
sodes (89%) and 65 episodes (89%), respectively. 
The median lumefantrine level was significantly 
higher in the lopinavir–ritonavir group than in 
the NNRTI group (926 ng per milliliter [inter-
quartile range, 473 to 1910] vs. 200 ng per milli-
liter [interquartile range, 108 to 510], P<0.001). 
In addition, in the NNRTI group, the median 
lumefantrine level on day 7 was significantly 
higher among the 67 patients who were taking 
nevirapine than among the 25 patients who were 
Table 2. Main Study Outcomes.
Outcome NNRTI-Based ART Lopinavir–Ritonavir–Based ART
Incidence-Rate Ratio
(95% CI) P Value
No. of  
Events
Person-Yr  
at Risk
Episodes/
Person-Yr
No. of  
Events
Person-Yr  
at Risk
Episodes/
Person-Yr
Episodes of malaria
All episodes 176 78.2 2.25 109 82.3 1.32 0.59 (0.36–0.97) 0.04
Complicated malaria 2 78.2 0.026 2 82.3 0.024 0.80 (0.06–11.16) 0.87
NNRTI-Based ART Lopinavir–Ritonavir–Based ART
Hazard Ratio with 
Lopinavir–Ritonavir
(95% CI) P Value
No. of 
Events Cumulative Risk
No. of  
Events Cumulative Risk
% (95% CI) % (95% CI)
Risk of malaria
6-mo risk of first episode  
of malaria*
42 52.5 (42.0–63.9) 33 40.7 (30.9–52.2) 0.71 (0.45–1.12) 0.14
28-day risk of recurrent  
parasitemia†
174 40.8 (33.9–48.6) 107 14.0 (8.7–22.2) 0.31 (0.14–0.68) 0.004
63-day risk of recurrent  
malaria†
174 54.2 (46.4–62.2) 107 28.1 (20.2–38.3) 0.41 (0.22–0.76) 0.004
* The 6-month risk of a first episode of malaria was assessed in 86 patients in the NNRTI group and 84 in the lopinavir–ritonavir group. 
Among patients who were followed for 6 months, malaria did not develop in 34 patients in the NNRTI group and 44 in the lopinavir–ritona-
vir group; data on 10 patients in the NNRTI group and 7 in the lopinavir–ritonavir group were censored before the 6-month follow-up as-
sessment.
† The risk of recurrence was assessed among patients who had had uncomplicated malaria that had been treated with artemether–lumefan-
trine.
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taking efavirenz (388 ng per milliliter [interquar-
tile range, 164 to 563] vs. 97 ng per milliliter 
[interquartile range, 61 to 124], P<0.001). There 
was no significant association between the lume-
fantrine level on day 7 and the 63-day risk of re-
current malaria in the NNRTI group. In contrast, 
in the lopinavir–ritonavir group, children with 
lumefantrine levels of 300 ng per milliliter or 
higher on day 7, as compared with children with 
lower drug levels, had a significantly reduced 
risk of recurrent malaria within 63 days (Fig. 3, 
and Table S3 in the Supplementary Appendix).
To determine whether there were direct anti-
malarial interactions between lopinavir and 
lumefantrine, two field isolates were cloned for 
in vitro drug-sensitivity testing. Modest synergy 
between lopinavir and lumefantrine was observed; 
data consistent with this are concave isobolo-
gram curves and mean fractional inhibitory 
concentrations near 0.5 (Fig. S1 in the Supple-
mentary Appendix).
Discussion
Among HIV-infected children in Uganda, a lopina-
vir–ritonavir–based antiretroviral regimen, as 
compared with an NNRTI-based regimen, re-
duced the incidence of malaria by 41%. The pri-
mary benefit in the lopinavir–ritonavir group 
was conferred by a dramatic reduction in the risk 
of recurrent malaria after treatment with arte-
mether–lumefantrine.
The protective effect of lopinavir–ritonavir 
against malaria could have resulted from direct 
antimalarial activity of lopinavir–ritonavir; inhi-
bition of lumefantrine metabolism after treat-
ment with artemether–lumefantrine, which would 
have extended the post-treatment prophylactic 
effect; or antimalarial synergy between lumefan-
trine and lopinavir. The possibility of direct an-
timalarial effects of HIV protease inhibitors is 
supported by in vitro studies showing activity of 
lopinavir at levels achievable in humans,3,5 in 
vivo studies showing activity against the rodent 
parasite P. chabaudi,5 activity against clinical iso-
lates of P. falciparum and P. vivax,14 in vitro activ-
ity against P. falciparum in serum samples from 
patients receiving protease inhibitors,15 and ac-
tion against P. falciparum cytoadherence and phago-
cytosis.16 In vitro antimalarial activity has not 
been reported with levels of NNRTIs that are 
attained with standard doses.2
The antimalarial activity of HIV protease in-
hibitors could theoretically be due to inhibition 
of plasmodial aspartic proteases that are bio-
chemically similar to the HIV protease.3,5 How-
ever, we found only a nonsignificant trend to-
ward a reduced risk of a first episode of malaria 
in the lopinavir–ritonavir group. Rather, protec-
tion against recurrent malaria accounted for most 
of the benefit of lopinavir–ritonavir, suggesting 
that the principal role of lopinavir–ritonavir with 
respect to protection against malaria is an effect 
on lumefantrine exposure. Children in the lopina-
vir–ritonavir group had significantly higher 
lumefantrine levels 7 days after the initiation of 
artemether–lumefantrine therapy than did chil-
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Figure 2. Selected Secondary Study Outcomes
Panel A shows Kaplan–Meier curves for the 6-month risk of a first episode of 
malaria, according to study group. Panel B shows Kaplan–Meier curves for 
the 63-day risk of recurrent malaria after treatment of malaria with artemether–
lumefantrine, according to study group.
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dren in the NNRTI group, and this effect was 
associated with a 59% reduction in the 63-day 
risk of recurrent malaria in the lopinavir–ritona-
vir group as compared with the NNRTI group. 
Increased lumefantrine exposure with concomi-
tant lopinavir–ritonavir therapy, which was 
thought to be the result of inhibition of cyto-
chrome P450 3A4 metabolism by ritonavir, was 
previously observed in healthy adults.6 In con-
trast, nevirapine and efavirenz both induce cyto-
chrome P450 3A4 pathways, and the concurrent 
administration of either of these drugs with 
artemether–lumefantrine might diminish lume-
fantrine exposure. However, day 7 lumefantrine 
levels in the nevirapine group were similar to 
those reported previously in HIV-uninfected 
children receiving artemether–lumefantrine,17 
suggesting that the greater protection in the 
lopinavir–ritonavir group than in the NNRTI 
group was due to inhibition of lumefantrine 
metabolism by lopinavir–ritonavir rather than to 
enhancement of cytochrome P450 3A4 metabo-
lism by the NNRTIs.
The higher lumefantrine levels in the lopina-
vir–ritonavir group were not associated with a 
significantly increased risk of adverse events, 
with the exception of pruritus. Halofantrine, a 
related drug, is associated with prolongation of 
the QT interval and cardiac rhythm disturbances. 
In this study, no episodes of prolongation of the 
QTc interval were observed 3 days after the ini-
tiation of artemether–lumefantrine.18 We noted 
a trend toward a higher risk of serious adverse 
events after antimalarial therapy in the lopina-
vir–ritonavir group, with two episodes of neutro-
penia possibly related to the study drug. Given 
our limited statistical power for the comparison 
of uncommon events in this study and our lim-
ited evaluation of potential cardiotoxic effects, 
future studies of the safety of coadministration 
of lopinavir–ritonavir and lumefantrine are war-
ranted. Increased lumefantrine exposure might 
also increase the selection of lumefantrine-resis-
tant parasites. Genetic polymorphisms associated 
with decreased activity are selected by arte-
mether–lumefantrine,19 suggesting that continued 
surveillance of the efficacy of artemether–lume-
fantrine therapy is warranted.
In vitro synergy in antimalarial activity be-
tween lopinavir and lumefantrine has been ob-
served in laboratory strains of P. falciparum2 and 
in two isolates obtained from children in this 
trial. Perhaps the synergistic antimalarial activ-
ity between lopinavir and lumefantrine enhanced 
the protective effect of prolonged lumefantrine 
exposure.
Our results suggest that a strategy of pharma-
cologic enhancement of exposure to antimalarial 
agents may be useful in reducing the burden of 
malaria, particularly in areas where the transmis-
sion intensity is high and recurrent malaria after 
treatment is commonplace. Although artemether–
lumefantrine was very effective in clearing infec-
tions, the high risk of recurrent malaria after 
therapy, even with the use of insecticide-treated 
bed nets and trimethoprim–sulfamethoxazole 
prophylaxis, highlights the importance of post-
treatment prophylaxis in high-transmission areas 
such as Uganda. In HIV-infected children requir-
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Figure 3. Kaplan–Meier Curves for the 63-Day Risk of Recurrent Malaria, 
According to Study Group and Lumefantrine Level on Day 7 after Initiation 
of Artemether–Lumefantrine Therapy.
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ing ART, it may be possible to use pharmacologic 
enhancement with lopinavir–ritonavir to provide 
protection from malaria. It is unlikely that an 
increase in the antimalarial dose without lopina-
vir–ritonavir therapy will achieve the same effect 
that we observed with lopinavir–ritonavir thera-
py in our cohort. The effects that are seen with 
increases in exposure of a drug may be several 
magnitudes greater than the effects that are pos-
sible with dose escalation — a finding that has 
been shown with respect to the enhancement of 
HIV protease inhibitors with ritonavir.20 In addi-
tion, lumefantrine exhibits saturable absorption, 
with the result that only modest increases in ex-
posure are seen after dose escalation.21
In a randomized trial comparing lopinavir–
ritonavir therapy with NNRTI therapy in children, 
virologic suppression rates were higher with lopin-
avir–ritonavir than with NNRTI — a finding that 
also supports the use of lopinavir–ritonavir.22,23 
However, before changes in policy are implement-
ed, the relative antiretroviral efficacies of various 
regimens should be studied further, the applica-
bility of our findings to areas with a lower inten-
sity of malaria transmission should be considered, 
and logistical challenges must be addressed. We 
are continuing to follow our cohort in order to 
evaluate long-term HIV efficacy outcomes. Previ-
ously, the high cost of the drugs and complex 
storage requirements represented considerable 
challenges in administering lopinavir–ritonavir in 
low-income countries. However, the declining cost 
of the drugs and the availability of a heat-stable 
lopinavir–ritonavir formulation suggest that these 
challenges are now surmountable. In conclusion, 
pharmacologic enhancement with the use of 
agents that alter drug metabolism may offer a 
means of improving the control of malaria.
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tional Institute of Child Health and Human Development.
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